Effect of sphingosine kinase modulators on interleukin-1β release, sphingosine 1-phosphate receptor 1 expression and experimental autoimmune encephalomyelitis : FTY720 analogues and inflammation
Barbour, Mark and McNaughton, Melissa and Boomkamp, Stephanie D. and MacRitchie, Neil and Jiang, Hui-Rong and Pyne, Nigel J and Pyne, Susan (2017) Effect of sphingosine kinase modulators on interleukin-1β release, sphingosine 1-phosphate receptor 1 expression and experimental autoimmune encephalomyelitis : FTY720 analogues and inflammation. British Journal of Pharmacology, 174 (2). pp. 210-222. ISSN 1476-5381
|
Text (Barbour-etal-BJP2016-Effect-of-sphingosine-kinase-modulators-on-interleukin-1β-release)
Barbour_etal_BJP2016_Effect_of_sphingosine_kinase_modulators_on_interleukin_1_release.pdf Accepted Author Manuscript Download (915kB)| Preview |
Abstract
Background and Purpose: The sphingosine analogue, FTY720 (Gilenya®) alleviates clinical disease progression in multiple sclerosis. Here we variously assessed the effects of an azide analogue of (S)-FTY720 vinylphosphonate (compound 5; a sphingosine kinase 1 activator), (R)-FTY720 methyl ether (ROMe, a sphingosine kinase 2 inhibitor) and RB-020 (a sphingosine kinase 1 inhibitor and sphingosine kinase 2 substrate) on IL-1beta formation, sphingosine 1-phosphate levels and S1P1 expression. We also assessed the effect of compound 5 and ROMe in an experimental autoimmune encephalomyelitis (EAE) model. Experimental Approach: We measured IL-1beta formation by macrophages, sphingosine 1-phosphate levels and S1P1 expression levels in vitro and clinical score and inflammatory cell infiltration into the spinal cord in vivo. Key Results: Treatment of differentiated U937 macrophages with compound 5, RB-020 or sphingosine (but not ROMe) enhanced IL-1beta release. This data suggests these compounds might be pro-inflammatory in vitro. However, compound 5 or ROMe reduced disease progression and infiltration of inflammatory cells into the spinal cord in EAE and ROMe induced a reduction in CD4+ and CD8+ T-cell levels in the blood (lymphopenia). Indeed, ROMe induced a marked decrease in cell surface S1P1 expression in vitro. Conclusion and Implications: This is the first demonstration that an activator of SK1 (compound 5) and an inhibitor of SK2 (ROMe, which also reduces cell surface S1P1 expression) have an anti-inflammatory action in EAE.
Creators(s): |
Barbour, Mark ![]() ![]() ![]() ![]() | Item type: | Article |
---|---|
ID code: | 58650 |
Notes: | This is the peer reviewed version of the following article: Barbour, M., McNaughton, M., Boomkamp, S. D., MacRitchie, N., Jiang, H-R., Pyne, N., & Pyne, S. (2016). Effect of sphingosine kinase modulators on interleukin-1β release, sphingosine 1-phosphate receptor 1 expression and experimental autoimmune encephalomyelitis: FTY720 analogues and inflammation. British Journal of Pharmacology, which has been published in final form at https://doi.org/10.1111/bph.13670. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. |
Keywords: | Sphingosine kinase, sphingosine 1-phosphate, inflammasome, multiple sclerosis, experimental autoimmune encephalomyelitis, autoimmune inflammatory demyelinating disease, T-lymphocytes, pathogen-associated molecular patterns, Immunology, Internal medicine, Immunology, Immunology and Allergy |
Subjects: | Science > Microbiology > Immunology Medicine > Internal medicine |
Department: | Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences |
Depositing user: | Pure Administrator |
Date deposited: | 15 Nov 2016 11:29 |
Last modified: | 03 Mar 2021 01:36 |
Related URLs: | |
URI: | https://strathprints.strath.ac.uk/id/eprint/58650 |
Export data: |